[{"id":"74310eb7-a8a1-44ad-bec4-8bd17dc1098e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04481009","created_at":"2021-01-18T21:31:27.775Z","updated_at":"2024-07-02T16:35:59.233Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04481009","lead_sponsor":"Eucure (Beijing) Biopharma Co., Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • YH003"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 05/16/2022","primary_completion_date":" 05/16/2022","study_txt":" Completion: 05/26/2022","study_completion_date":" 05/26/2022","last_update_posted":"2022-12-12"}]